154 related articles for article (PubMed ID: 36614918)
1. Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy.
De Franceschi L; Castiglioni C; Condorelli C; Valsecchi D; Premoli E; Fiocchi C; Perrone V; Esposti LD; Forni GL; On Behalf Of The GREATalyS Study Group
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614918
[TBL] [Abstract][Full Text] [Related]
2. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
Udeze C; Evans KA; Yang Y; Lillehaugen T; Manjelievskaia J; Mujumdar U; Li N; Andemariam B
Adv Ther; 2023 Aug; 40(8):3543-3558. PubMed ID: 37332020
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database.
Leleu H; Arlet JB; Habibi A; Etienne-Julan M; Khellaf M; Adjibi Y; Pirenne F; Pitel M; Granghaud A; Sinniah C; De Montalembert M; Galacteros F
PLoS One; 2021; 16(7):e0253986. PubMed ID: 34242255
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and cost of sickle cell disease in France: real-world analysis using data from the Echantillon Généraliste des Bénéficiaires.
Beillat M; Durand-Zaleski I; Pirenne F; Bénard S; Chillotti L; Galacteros F
Front Public Health; 2023; 11():1215605. PubMed ID: 37808997
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis.
Gallagher ME; Chawla A; Brady BL; Badawy SM
J Med Econ; 2022; 25(1):1140-1148. PubMed ID: 36222016
[TBL] [Abstract][Full Text] [Related]
6. Sickle cell disease complications: Prevalence and resource utilization.
Shah N; Bhor M; Xie L; Paulose J; Yuce H
PLoS One; 2019; 14(7):e0214355. PubMed ID: 31276525
[TBL] [Abstract][Full Text] [Related]
7. Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study.
Shah N; Bhor M; Xie L; Paulose J; Yuce H
J Health Econ Outcomes Res; 2020; 7(1):52-60. PubMed ID: 32685598
[TBL] [Abstract][Full Text] [Related]
8. An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes.
Bou-Maroun LM; Meta F; Hanba CJ; Campbell AD; Yanik GA
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28801954
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of diverticular disease: An observational analysis based on real world data from an Italian region.
Mennini FS; Sciattella P; Marcellusi A; Toraldo B; Koch M
Dig Liver Dis; 2017 Sep; 49(9):1003-1008. PubMed ID: 28663067
[TBL] [Abstract][Full Text] [Related]
10. Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers.
Shah NR; Bhor M; Latremouille-Viau D; Kumar Sharma V; Puckrein GA; Gagnon-Sanschagrin P; Khare A; Kumar Singh M; Serra E; Davidson M; Xu L; Guerin A
J Med Econ; 2020 Nov; 23(11):1345-1355. PubMed ID: 32815766
[TBL] [Abstract][Full Text] [Related]
11. Patient-Reported Outcomes and Economic Burden of Adults with Sickle Cell Disease in the United States: A Systematic Review.
Lee S; Vania DK; Bhor M; Revicki D; Abogunrin S; Sarri G
Int J Gen Med; 2020; 13():361-377. PubMed ID: 32753936
[TBL] [Abstract][Full Text] [Related]
12. High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study.
Kanter J; Bhor M; Li X; Li FY; Paulose J
J Health Econ Outcomes Res; 2019; 6(3):174-184. PubMed ID: 32685589
[TBL] [Abstract][Full Text] [Related]
13. A retrospective analysis of the cost of hospitalizations for sickle cell disease with crisis in England, 2010/11.
Pizzo E; Laverty AA; Phekoo KJ; AlJuburi G; Green SA; Bell D; Majeed A
J Public Health (Oxf); 2015 Sep; 37(3):529-39. PubMed ID: 24796312
[TBL] [Abstract][Full Text] [Related]
14. Preoperative blood transfusions for sickle cell disease.
Estcourt LJ; Kimber C; Trivella M; Doree C; Hopewell S
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003149. PubMed ID: 32614473
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of sickle cell disease in Brazil.
Silva-Pinto AC; Costa FF; Gualandro SFM; Fonseca PBB; Grindler CM; Souza Filho HCR; Bueno CT; Cançado RD
PLoS One; 2022; 17(6):e0269703. PubMed ID: 35709301
[TBL] [Abstract][Full Text] [Related]
16. Impact of Hydroxyurea Therapy in Reducing Pain Crises, Hospital Admissions, and Length of Stay Among Sickle Cell Patients in the Eastern Region of Saudi Arabia.
Albohassan H; Ammen M; Alomran AA; Bu Shehab H; Al Sakkak H; Al Bohassan A
Cureus; 2022 Nov; 14(11):e31527. PubMed ID: 36540486
[TBL] [Abstract][Full Text] [Related]
17. Hospitalisations for sickle-cell disease in an Australian paediatric population.
Teoh Y; Greenway A; Savoia H; Monagle P; Roy J; Barnes C
J Paediatr Child Health; 2013 Jan; 49(1):68-71. PubMed ID: 23198729
[TBL] [Abstract][Full Text] [Related]
18. Real-world evidence of the burden of sickle cell disease: a 5-year longitudinal study at a Brazilian reference center.
Barros GDS; Leal CVF; Leite LAC; Fujimoto DE; Cançado RD
Hematol Transfus Cell Ther; 2024; 46(2):161-166. PubMed ID: 38307824
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology, Patients' Journey and Healthcare Costs in Early-Stage Non-Small-Cell Lung Carcinoma: A Real-World Evidence Analysis in Italy.
Cortinovis DL; Perrone V; Giacomini E; Sangiorgi D; Andretta M; Bartolini F; Taurino G; Belfiore M; Sicari E; Degli Esposti L
Pharmaceuticals (Basel); 2023 Feb; 16(3):. PubMed ID: 36986463
[TBL] [Abstract][Full Text] [Related]
20. Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy.
Antonini G; Habetswallner F; Inghilleri M; Mantegazza R; Rodolico C; Saccà F; Sgarzi M; deRuyck F; Paci S; Phillips G; Crippa L; Veronesi C; Perrone V; Degli Esposti L;
Heliyon; 2023 Jun; 9(6):e16367. PubMed ID: 37274644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
